{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:26:01Z","timestamp":1785767161885,"version":"3.56.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Guangxi Key Laboratory of Precision Medicine in Cardio-Cerebrovascular Diseases Control and Prevention","award":["19-245-34"],"award-info":[{"award-number":["19-245-34"]}]},{"name":"Guangxi Clinical Research Center for Cardio-Cerebrovascular Diseases","award":["AD17129014"],"award-info":[{"award-number":["AD17129014"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06544-2","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T05:54:50Z","timestamp":1756101290000},"page":"5797-5808","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lymphoma and Long-Term cardiovascular disease risk: A comprehensive analysis from the UK biobank"],"prefix":"10.1007","volume":"104","author":[{"given":"Chenliang","family":"Ge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"6544_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-019-0799-1","volume":"12","author":"L Zhou","year":"2019","unstructured":"Zhou L et al (2019) Global, regional, and National burden of hodgkin lymphoma from 1990 to 2017: estimates from the 2017 global burden of disease study. J Hematol Oncol 12:1\u201313","journal-title":"J Hematol Oncol"},{"key":"6544_CR2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.puhe.2023.11.023","volume":"226","author":"Z Shen","year":"2024","unstructured":"Shen Z et al (2024) The global burden of lymphoma: estimates from the global burden of disease 2019 study. Public Health 226:199\u2013206","journal-title":"Public Health"},{"key":"6544_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s11899-017-0382-1","volume":"12","author":"U Zahid","year":"2017","unstructured":"Zahid U et al (2017) A review of autologous stem cell transplantation in lymphoma. Curr Hematol Malig Rep 12:217\u2013226","journal-title":"Curr Hematol Malig Rep"},{"key":"6544_CR4","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/ajh.25460","volume":"94","author":"Y Liu","year":"2019","unstructured":"Liu Y, Barta SK (2019) Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol 94:604\u2013616","journal-title":"Am J Hematol"},{"key":"6544_CR5","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1182\/blood-2016-09-740332","volume":"129","author":"FA Van Nimwegen","year":"2017","unstructured":"Van Nimwegen FA et al (2017) Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. Blood 129:2257\u20132265","journal-title":"Blood"},{"key":"6544_CR6","doi-asserted-by":"publisher","first-page":"e2254669","DOI":"10.1001\/jamanetworkopen.2022.54669","volume":"6","author":"CM Larsen","year":"2023","unstructured":"Larsen CM et al (2023) Association of anthracycline with heart failure in patients treated for breast cancer or lymphoma, 1985\u20132010. JAMA Netw Open 6:e2254669\u2013e2254669","journal-title":"JAMA Netw Open"},{"issue":"1","key":"6544_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1182\/asheducation-2016.1.323","volume":"2016","author":"FE van Leeuwen","year":"2016","unstructured":"van Leeuwen FE, Ng AK (2016) Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment. Hematology Am Soc Hematol Educ Program Book 2016(1):323\u2013330. https:\/\/doi.org\/10.1182\/asheducation-2016.1.323","journal-title":"Hematology Am Soc Hematol Educ Program Book"},{"key":"6544_CR8","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1200\/JCO.2015.64.0409","volume":"34","author":"SH Armenian","year":"2016","unstructured":"Armenian SH et al (2016) Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study. J Clin Oncol 34:1122\u20131130","journal-title":"J Clin Oncol"},{"key":"6544_CR9","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.2174\/1381612825666190925163827","volume":"25","author":"GD Flora","year":"2019","unstructured":"Flora GD, Nayak MK (2019) A brief review of cardiovascular diseases, associated risk factors and current treatment regimes. Curr Pharm Des 25:4063\u20134084","journal-title":"Curr Pharm Des"},{"key":"6544_CR10","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","volume":"133","author":"RJ Koene","year":"2016","unstructured":"Koene RJ, Prizment AE, Blaes A, Konety SH (2016) Shared risk factors in cardiovascular disease and cancer. Circulation 133:1104\u20131114","journal-title":"Circulation"},{"key":"6544_CR11","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","volume":"40","author":"KM Sturgeon","year":"2019","unstructured":"Sturgeon KM et al (2019) A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J 40:3889\u20133897","journal-title":"Eur Heart J"},{"key":"6544_CR12","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1200\/JCO.2008.20.2267","volume":"28","author":"M Tukenova","year":"2010","unstructured":"Tukenova M et al (2010) Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol 28:1308\u20131315","journal-title":"J Clin Oncol"},{"key":"6544_CR13","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.jacc.2014.06.1167","volume":"64","author":"P Vejpongsa","year":"2014","unstructured":"Vejpongsa P, Yeh ET (2014) Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol 64:938\u2013945","journal-title":"J Am Coll Cardiol"},{"key":"6544_CR14","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL et al (2016) 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European society of cardiology (ESC). Eur Heart J 37:2768\u20132801","journal-title":"Eur Heart J"},{"key":"6544_CR15","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1038\/s41467-020-15948-9","volume":"11","author":"TJ Littlejohns","year":"2020","unstructured":"Littlejohns TJ et al (2020) The UK biobank imaging enhancement of 100,000 participants: rationale, data collection, management and future directions. Nat Commun 11:2624","journal-title":"Nat Commun"},{"key":"6544_CR16","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1146\/annurev-genom-121321-093606","volume":"23","author":"VY Tan","year":"2022","unstructured":"Tan VY, Timpson NJ (2022) The UK biobank: a shining example of genome-wide association study science with the power to detect the murky complications of real-world epidemiology. Annu Rev Genom Hum Genet 23:569\u2013589","journal-title":"Annu Rev Genom Hum Genet"},{"key":"6544_CR17","first-page":"1","volume":"25","author":"EA Stuart","year":"2010","unstructured":"Stuart EA (2010) Matching methods for causal inference: a review and a look forward. Stat Sci Rev J Inst Math Stat 25:1","journal-title":"Stat Sci Rev J Inst Math Stat"},{"key":"6544_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","volume":"45","author":"S Van Buuren","year":"2011","unstructured":"Van Buuren S, Groothuis-Oudshoorn K (2011) Mice: multivariate imputation by chained equations in R. J Stat Softw 45:1\u201367","journal-title":"J Stat Softw"},{"key":"6544_CR19","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc: Ser B (Methodol) 57:289\u2013300","journal-title":"J Roy Stat Soc: Ser B (Methodol)"},{"key":"6544_CR20","doi-asserted-by":"publisher","first-page":"692142","DOI":"10.3389\/fonc.2021.692142","volume":"11","author":"AE Kartikasari","year":"2021","unstructured":"Kartikasari AE, Huertas CS, Mitchell A, Plebanski M (2021) Tumor-induced inflammatory cytokines and the emerging diagnostic devices for cancer detection and prognosis. Front Oncol 11:692142","journal-title":"Front Oncol"},{"key":"6544_CR21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","volume":"120","author":"P Berraondo","year":"2019","unstructured":"Berraondo P et al (2019) Cytokines in clinical cancer immunotherapy. Br J Cancer 120:6\u201315","journal-title":"Br J Cancer"},{"key":"6544_CR22","doi-asserted-by":"publisher","first-page":"1509100","DOI":"10.3389\/fonc.2024.1509100","volume":"14","author":"S Zhuang","year":"2025","unstructured":"Zhuang S et al (2025) Primary cardiac lymphoma: a clinicopathological study of 121 cases. Front Oncol 14:1509100","journal-title":"Front Oncol"},{"issue":"4","key":"6544_CR23","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1634\/theoncologist.2016-0289","volume":"22","author":"J Olivieri","year":"2017","unstructured":"Olivieri J et al (2017) Modern management of anthracycline-induced cardiotoxicity in lymphoma patients: low occurrence of cardiotoxicity with comprehensive assessment and tailored substitution by nonpegylated liposomal doxorubicin. Oncologist 22(4):422\u2013431. https:\/\/doi.org\/10.1634\/theoncologist.2016-0289","journal-title":"Oncologist"},{"key":"6544_CR24","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/1471-2407-10-337","volume":"10","author":"LA Smith","year":"2010","unstructured":"Smith LA et al (2010) Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 10:337. https:\/\/doi.org\/10.1186\/1471-2407-10-337","journal-title":"BMC Cancer"},{"key":"6544_CR25","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.yjmcc.2012.03.006","volume":"52","author":"Y Octavia","year":"2012","unstructured":"Octavia Y et al (2012) Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 52:1213\u20131225. https:\/\/doi.org\/10.1016\/j.yjmcc.2012.03.006","journal-title":"J Mol Cell Cardiol"},{"key":"6544_CR26","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/jcm11010146","volume":"11","author":"JA Quintero-Martinez","year":"2021","unstructured":"Quintero-Martinez JA, Cordova-Madera SN, Villarraga HR (2021) Radiation-induced heart disease. J Clin Med 11:146","journal-title":"J Clin Med"},{"key":"6544_CR27","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jaccao.2021.06.007","volume":"3","author":"C Bergom","year":"2021","unstructured":"Bergom C et al (2021) Past, present, and future of radiation-induced cardiotoxicity: refinements in targeting, surveillance, and risk stratification. JACC: CardioOncology 3:343\u2013359. https:\/\/doi.org\/10.1016\/j.jaccao.2021.06.007","journal-title":"JACC: CardioOncology"},{"key":"6544_CR28","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.cdtm.2019.02.004","volume":"5","author":"S Upadhrasta","year":"2019","unstructured":"Upadhrasta S, Elias H, Patel K, Zheng L (2019) Managing cardiotoxicity associated with immune checkpoint inhibitors. Chronic Dis Transl Med 5:6\u201314. https:\/\/doi.org\/10.1016\/j.cdtm.2019.02.004","journal-title":"Chronic Dis Transl Med"},{"key":"6544_CR29","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235\u2013242. https:\/\/doi.org\/10.1056\/NEJMoa011795","journal-title":"N Engl J Med"},{"key":"6544_CR30","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/ng.3374","volume":"47","author":"F Aminkeng","year":"2015","unstructured":"Aminkeng F et al (2015) A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nat Genet 47:1079\u20131084. https:\/\/doi.org\/10.1038\/ng.3374","journal-title":"Nat Genet"},{"key":"6544_CR31","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jaccao.2020.09.006","volume":"2","author":"S Bhatia","year":"2020","unstructured":"Bhatia S (2020) Genetics of anthracycline cardiomyopathy in cancer survivors: JACC: cardiooncology State-of-the-Art review. JACC: CardioOncology 2:539\u2013552. https:\/\/doi.org\/10.1016\/j.jaccao.2020.09.006","journal-title":"JACC: CardioOncology"},{"key":"6544_CR32","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1002\/hsr2.135","volume":"2","author":"CR Stone","year":"2019","unstructured":"Stone CR et al (2019) Treatment for lymphoma and late cardiovascular disease risk: A systematic review and meta-analysis. Health Sci Rep 2:e135. https:\/\/doi.org\/10.1002\/hsr2.135","journal-title":"Health Sci Rep"},{"key":"6544_CR33","first-page":"695","volume":"3","author":"N van der Velde","year":"2021","unstructured":"van der Velde N et al (2021) Detection of subclinical cardiovascular disease by cardiovascular magnetic resonance in lymphoma survivors. JACC: CardioOncology 3:695\u2013706","journal-title":"JACC: CardioOncology"},{"key":"6544_CR34","doi-asserted-by":"publisher","first-page":"7505","DOI":"10.1200\/JCO.2016.34.15_suppl.7505","volume":"34","author":"C Dartigeas","year":"2016","unstructured":"Dartigeas C et al (2016) Rituximab maintenance after induction with abbreviated FCR in previously untreated elderly (\u2265 65 years) CLL patients: results of the randomized CLL 2007 SA trial from the French FILO group (NCT00645606). J Clin Oncol 34:7505\u20137505. https:\/\/doi.org\/10.1200\/JCO.2016.34.15_suppl.7505","journal-title":"J Clin Oncol"},{"key":"6544_CR35","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1002\/ajh.26230","volume":"96","author":"NJ Boddicker","year":"2021","unstructured":"Boddicker NJ et al (2021) Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era. Am J Hematol 96:979\u2013988. https:\/\/doi.org\/10.1002\/ajh.26230","journal-title":"Am J Hematol"},{"key":"6544_CR36","doi-asserted-by":"publisher","first-page":"ehae666.3175","DOI":"10.1093\/eurheartj\/ehae666.3175","volume":"45","author":"SJ Godtfredsen","year":"2024","unstructured":"Godtfredsen SJ et al (2024) Risk of cardiovascular disease in Hodgkin lymphoma patients. Eur Heart J 45:ehae666.3175. https:\/\/doi.org\/10.1093\/eurheartj\/ehae666.3175","journal-title":"Eur Heart J"},{"key":"6544_CR37","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1182\/blood-2016-09-740332","volume":"129","author":"FA van Nimwegen","year":"2017","unstructured":"van Nimwegen FA et al (2017) Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. Blood 129:2257\u20132265. https:\/\/doi.org\/10.1182\/blood-2016-09-740332","journal-title":"Blood"},{"key":"6544_CR38","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","volume":"175","author":"FA van Nimwegen","year":"2015","unstructured":"van Nimwegen FA et al (2015) Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med 175:1007\u20131017. https:\/\/doi.org\/10.1001\/jamainternmed.2015.1180","journal-title":"JAMA Intern Med"},{"issue":"15","key":"6544_CR39","doi-asserted-by":"publisher","first-page":"10001","DOI":"10.1200\/JCO.2016.34.15_suppl.10001","volume":"34","author":"DL Hershman","year":"2016","unstructured":"Hershman DL et al (2016) Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants in SWOG clinical trials. J Clin Oncol 34(15):10001. https:\/\/doi.org\/10.1200\/JCO.2016.34.15_suppl.10001","journal-title":"J Clin Oncol"},{"key":"6544_CR40","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3390\/cancers14010061","volume":"14","author":"S Oliva","year":"2021","unstructured":"Oliva S et al (2021) Late cardiological sequelae and long-term monitoring in classical Hodgkin lymphoma and diffuse large B-cell lymphoma survivors: a systematic review by the Fondazione Italiana Linfomi. Cancers (Basel) 14:61","journal-title":"Cancers (Basel)"},{"key":"6544_CR41","doi-asserted-by":"publisher","first-page":"792","DOI":"10.6004\/jnccn.2023.0041","volume":"21","author":"T Sanft","year":"2023","unstructured":"Sanft T et al (2023) NCCN guidelines\u00ae insights: survivorship, version 1.2023: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 21:792\u2013803","journal-title":"J Natl Compr Canc Netw"},{"key":"6544_CR42","first-page":"438","volume":"74","author":"AM Garc\u00eda","year":"2021","unstructured":"Garc\u00eda AM et al (2021) Stratification and management of cardiovascular risk in cancer patients. A consensus document of the SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AEEC, and AECC. Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition) 74:438\u2013448","journal-title":"Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"},{"key":"6544_CR43","doi-asserted-by":"publisher","first-page":"5885","DOI":"10.3390\/cancers15245885","volume":"15","author":"A Pons-Riverola","year":"2023","unstructured":"Pons-Riverola A et al (2023) Developing cardio-oncology programs in the new era: beyond ventricular dysfunction due to cancer treatments. Cancers (Basel) 15:5885","journal-title":"Cancers (Basel)"},{"key":"6544_CR44","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1002\/ehf2.13879","volume":"9","author":"A Cuomo","year":"2022","unstructured":"Cuomo A et al (2022) Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients. ESC Heart Fail 9:1666\u20131676","journal-title":"ESC Heart Fail"},{"key":"6544_CR45","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.3390\/cancers13133135","volume":"13","author":"C Minoia","year":"2021","unstructured":"Minoia C et al (2021) The impact of healthy lifestyles on late sequelae in classical Hodgkin lymphoma and diffuse large B-cell lymphoma survivors. A systematic review by the Fondazione Italiana Linfomi. Cancers (Basel) 13:3135","journal-title":"Cancers (Basel)"},{"key":"6544_CR46","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2165\/00024669-200504030-00006","volume":"4","author":"TM Dando","year":"2005","unstructured":"Dando TM, Keating GM (2005) Liposomal doxorubicin: a review of its use in metastatic breast cancer and potential in non-Hodgkin lymphoma. Am J Cancer 4:193\u2013206","journal-title":"Am J Cancer"},{"key":"6544_CR47","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/bjh.18348","volume":"198","author":"M Picardi","year":"2022","unstructured":"Picardi M et al (2022) Liposomal doxorubicin supercharge-containing front\u2010line treatment in patients with advanced\u2010stage diffuse large B\u2010cell lymphoma or classical Hodgkin lymphoma: preliminary results of a single\u2010centre phase II study. Br J Haematol 198:847\u2013860","journal-title":"Br J Haematol"},{"key":"6544_CR48","doi-asserted-by":"publisher","first-page":"e70003","DOI":"10.1002\/hon.70003","volume":"42","author":"M Picardi","year":"2024","unstructured":"Picardi M et al (2024) Liposomal doxorubicin, vinblastine and dacarbazine plus consolidation radiotherapy of residual nodal masses for frontline treatment in older adults with advanced stage classic Hodgkin lymphoma: improved outcome in a multi\u2010center real\u2010life study. Hematol Oncol 42:e70003","journal-title":"Hematol Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06544-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06544-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06544-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T02:30:51Z","timestamp":1764729051000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06544-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":48,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["6544"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06544-2","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"assertion":[{"value":"16 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}